N
Nils-Olof Bengtsson
Researcher at Umeå University
Publications - 12
Citations - 1085
Nils-Olof Bengtsson is an academic researcher from Umeå University. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 12, co-authored 12 publications receiving 1000 citations.
Papers
More filters
Journal ArticleDOI
Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden
Paul McGale,Sarah C. Darby,Per Hall,Jan Adolfsson,Nils-Olof Bengtsson,Anna M. Bennet,Tommy Fornander,Bruna Gigante,Maj-Britt Jensen,Richard Peto,Kazem Rahimi,Carolyn W. Taylor,Marianne Ewertz +12 more
TL;DR: Breast cancer radiotherapy has, at least until recently, increased the risk of developing ischaemic heart disease, pericarditis and valvular disease and women with ischaemia heart disease before breast cancer diagnosis may have incurred higher risks than others.
Journal ArticleDOI
HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review.
Jörgen Carlsson,Hans Nordgren,Johanna Sjöström,Kenneth Wester,K. Villman,Nils-Olof Bengtsson,Bjørn Østenstad,Hans Lundqvist,Carl Blomqvist +8 more
TL;DR: It is concluded that breast cancer lymph node metastases generally overexpress HER2 to the same extent as the corresponding primary tumours, and this also seems to be the case when distant metastases are considered.
Journal ArticleDOI
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.
TL;DR: It is suggested that cyclin D1 overexpression predicts for tamoxifen treatment resistance in breast cancer, which is in line with recent experimental data using breast cancer cell lines and overeexpression systems.
Journal ArticleDOI
Coronary Heart Disease Mortality After 5 Years of Adjuvant Tamoxifen Therapy: Results from a Randomized Trial
Bo Nordenskjöld,Johan Rosell,L E Rutqvist,Per-Olof Malmström,Jonas Bergh,Nils-Olof Bengtsson,Thomas Hatschek,Arne Wallgren,John Carstensen +8 more
TL;DR: Among the 2046 patients randomly assigned to the 5-year group all-cause mortality, breast cancer-specific mortality, and the incidence of contralateral breast cancer were reduced, compared with those among 2129 patients randomized in the 2- year group, butthe incidence of endometrial cancer was increased.
Journal ArticleDOI
TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer
Kenneth Villman,Johanna Sjöström,Reino Heikkilä,Ragnar Hultborn,Per-Uno Malmström,Nils-Olof Bengtsson,Martin Söderberg,Eero Saksela,Carl Blomqvist +8 more
TL;DR: The purpose of this study was to evaluate amplification of topoisomerase IIalpha (TOP2A) and HER2 genes as predictors of response to chemotherapy in advanced breast cancer.